Silverarc Capital Management, LLC is an SEC-registered investment adviser based in Boston, MA that reports managing 2 hedge funds on Form ADV. It reports $1.6 billion in regulatory assets under management. Its private funds, of all types, hold $935.3 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +28.2% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +113.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $1.6 billionForm ADV Item 5.F
- Gross assets of private funds
- $935.3 millionAll private fund types, Form ADV
- Hedge funds managed
- 23 private funds in total
- Employees
- 9Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 304220
- Latest Form ADV
- 03/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +20.4% | +14.8% |
| Q1 2026 | +6.5% | -4.6% |
| Q4 2025 | +26.1% | +2.4% |
| Q3 2025 | +32.4% | +7.8% |
| Q2 2025 | +13.7% | +10.4% |
| Q1 2025 | -12.1% | -4.5% |
| Q4 2024 | -4.5% | +2.1% |
| Q3 2024 | +4.6% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 63 share positions ($820,947,677) reported by Silverarc Capital Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 12, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Kodiak Sciences Inc8.66%
- Celcuity Inc7.78%
- Cogent Biosciences Inc6.14%
- Urogen Pharma LTD5.68%
- Immunome Inc5.48%
- Monte Rosa Therapeutics Inc4.52%
- Sagimet Biosciences Inc4.51%
- Ascendis Pharma A/s4.22%
- Rhythm Pharmaceuticals Inc4.04%
- Biogen Inc3.10%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Kodiak Sciences Inc | $71,116,116 | 8.66% | 750,170 | +37.33% |
| Celcuity Inc | $63,869,907 | 7.78% | 803,193 | +60.32% |
| Cogent Biosciences Inc | $50,421,830 | 6.14% | 1,574,698 | +22.96% |
| Urogen Pharma LTD | $46,671,234 | 5.68% | 1,148,689 | -11.77% |
| Immunome Inc | $45,014,300 | 5.48% | 2,092,715 | +3.75% |
| Monte Rosa Therapeutics Inc | $37,135,382 | 4.52% | 3,112,773 | -6.38% |
| Sagimet Biosciences Inc | $37,010,381 | 4.51% | 3,745,990 | +27.95% |
| Ascendis Pharma A/s | $34,670,030 | 4.22% | 152,175 | -26.21% |
| Rhythm Pharmaceuticals Inc | $33,165,003 | 4.04% | 348,317 | +11.83% |
| Biogen Inc | $25,477,005 | 3.10% | 112,790 | +134.49% |
| Immunovant Inc | $21,080,578 | 2.57% | 624,055 | +0.80% |
| Dianthus Therapeutics Inc | $20,831,045 | 2.54% | 236,582 | -39.34% |
| Oruka Therapeutics Inc | $20,649,090 | 2.52% | 247,918 | -29.73% |
| Erasca Inc | $19,504,470 | 2.38% | 1,330,455 | +5.34% |
| Abivax SA | $17,397,715 | 2.12% | 175,699 | +3.60% |
| Celldex Therapeutics Inc New | $15,802,759 | 1.92% | 487,589 | New |
| Ovid Therapeutics Inc | $14,815,500 | 1.80% | 5,950,000 | +91.87% |
| Spyre Therapeutics Inc | $13,456,974 | 1.64% | 151,151 | +152.09% |
| Definium Therapeutics Inc | $13,166,705 | 1.60% | 345,946 | -13.51% |
| Helix Acquisition Corp III | $12,829,279 | 1.56% | 1,208,030 | +2.56% |
| Alkermes PLC | $12,173,302 | 1.48% | 300,427 | +164.71% |
| C4 Therapeutics Inc | $11,503,975 | 1.40% | 3,454,647 | +13.94% |
| Avalyn Pharmaceuticals Inc | $10,779,248 | 1.31% | 378,352 | +14.48% |
| Cerus Corp | $9,402,416 | 1.15% | 3,950,595 | +13.76% |
| Alx Oncology Hldgs Inc | $9,126,684 | 1.11% | 6,565,960 | +14.29% |
| Zenas Biopharma Inc | $9,009,517 | 1.10% | 334,057 | -34.47% |
| Compass Pathways PLC | $8,923,909 | 1.09% | 717,356 | +42.51% |
| Rainier Acquisition Corp | $8,709,525 | 1.06% | 853,875 | New |
| Compugen LTD | $8,536,548 | 1.04% | 3,586,785 | +12.64% |
| Savara Inc | $7,837,178 | 0.95% | 1,518,833 | +12.05% |
| Vaxcyte Inc | $7,117,052 | 0.87% | 125,080 | -13.74% |
| Yarrow Bioscience Inc | $6,799,216 | 0.83% | 301,919 | New |
| Ibio Inc | $6,321,364 | 0.77% | 5,357,088 | +52.17% |
| Arcturus Therapeutics Hldgs | $6,296,017 | 0.77% | 459,899 | New |
| Praxis Precision Medicines I | $5,752,666 | 0.70% | 19,753 | -69.92% |
| Kiniksa Pharmaceuticals Intl | $5,647,753 | 0.69% | 75,697 | New |
| Enliven Therapeutics Inc | $5,567,360 | 0.68% | 121,452 | -75.18% |
| Solid Biosciences Inc | $5,497,237 | 0.67% | 760,337 | +13.75% |
| Evommune Inc | $4,906,663 | 0.60% | 594,027 | New |
| Syndax Pharmaceuticals Inc | $4,651,458 | 0.57% | 247,418 | -79.63% |
| Benitec Biopharma Inc | $4,431,090 | 0.54% | 443,109 | -34.82% |
| Research Alliance Corp III | $4,383,204 | 0.53% | 404,728 | +12.42% |
| Blossomhill Therapeutics Inc | $3,767,219 | 0.46% | 202,104 | New |
| Faeth Therapeutics Inc | $3,690,675 | 0.45% | 124,098 | New |
| Abeona Therapeutics Inc | $3,640,565 | 0.44% | 693,441 | +13.60% |
| Research Alliance Corp IV | $3,501,916 | 0.43% | 301,962 | New |
| Adlai Nortye LTD | $3,465,872 | 0.42% | 216,617 | New |
| Palisade Bio Inc | $3,153,063 | 0.38% | 2,335,602 | New |
| Disc Medicine Inc | $3,097,044 | 0.38% | 47,312 | -42.86% |
| Tela Bio Inc | $2,457,781 | 0.30% | 2,137,201 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 15 new positions, 17 sold out, 25 increased, 21 reduced and 2 unchanged.
Number of positions (a count, not dollars)
- New positions15
- Increased25
- Unchanged2
- Reduced21
- Sold out17
New positions
| Stock | Value | Shares |
|---|---|---|
| Celldex Therapeutics Inc New | $15,802,759 | 487,589 |
| Rainier Acquisition Corp | $8,709,525 | 853,875 |
| Yarrow Bioscience Inc | $6,799,216 | 301,919 |
| Arcturus Therapeutics Hldgs | $6,296,017 | 459,899 |
| Kiniksa Pharmaceuticals Intl | $5,647,753 | 75,697 |
| Evommune Inc | $4,906,663 | 594,027 |
| Blossomhill Therapeutics Inc | $3,767,219 | 202,104 |
| Faeth Therapeutics Inc | $3,690,675 | 124,098 |
| Research Alliance Corp IV | $3,501,916 | 301,962 |
| Adlai Nortye LTD | $3,465,872 | 216,617 |
| Palisade Bio Inc | $3,153,063 | 2,335,602 |
| Zevra Therapeutics Inc | $2,196,852 | 200,260 |
| Moderna Inc | $1,925,700 | 10,000 |
| Rapport Therapeutics Inc | $1,193,606 | 35,524 |
| Zura Bio LTD | $416,000 | 100,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Veracyte Inc | $18,676,199 | 318,001 |
| Guardant Health Inc | $14,976,895 | 99,826 |
| Trevi Therapeutics Inc | $12,646,472 | 678,095 |
| Veradermics Inc | $11,679,300 | 95,000 |
| Xenon Pharmaceuticals Inc | $11,276,516 | 186,821 |
| Avalo Therapeutics Inc | $9,247,429 | 500,402 |
| Genedx Holdings Corp | $8,393,767 | 122,269 |
| Artiva Biotherapeutics Inc | $5,092,500 | 525,000 |
| Insmed Inc | $3,671,780 | 34,438 |
| Karyopharm Therapeutics Inc | $2,906,184 | 297,460 |
| Revolution Medicines Inc | $1,872,800 | 10,000 |
| Sionna Therapeutics Inc | $1,868,607 | 42,478 |
| Fractyl Health Inc | $1,301,208 | 1,637,976 |
| Connect Biopharma Hldgs LTD | $1,297,100 | 545,000 |
| Crescent Biopharma Inc. | $1,063,872 | 59,104 |
| Foghorn Therapeutics Inc | $224,358 | 45,975 |
| Rocket Pharmaceuticals Inc | $356 | 104,828 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Celcuity Inc | +302,197 | +60.32% | $63,869,907 | 803,193 |
| Kodiak Sciences Inc | +203,914 | +37.33% | $71,116,116 | 750,170 |
| Biogen Inc | +64,689 | +134.49% | $25,477,005 | 112,790 |
| Cogent Biosciences Inc | +293,991 | +22.96% | $50,421,830 | 1,574,698 |
| Spyre Therapeutics Inc | +91,192 | +152.09% | $13,456,974 | 151,151 |
| Sagimet Biosciences Inc | +818,292 | +27.95% | $37,010,381 | 3,745,990 |
| Alkermes PLC | +186,933 | +164.71% | $12,173,302 | 300,427 |
| Ovid Therapeutics Inc | +2,848,871 | +91.87% | $14,815,500 | 5,950,000 |
| Rhythm Pharmaceuticals Inc | +36,856 | +11.83% | $33,165,003 | 348,317 |
| Compass Pathways PLC | +213,974 | +42.51% | $8,923,909 | 717,356 |
| Ibio Inc | +1,836,598 | +52.17% | $6,321,364 | 5,357,088 |
| Immunome Inc | +75,706 | +3.75% | $45,014,300 | 2,092,715 |
| C4 Therapeutics Inc | +422,587 | +13.94% | $11,503,975 | 3,454,647 |
| Avalyn Pharmaceuticals Inc | +47,865 | +14.48% | $10,779,248 | 378,352 |
| Alx Oncology Hldgs Inc | +821,203 | +14.29% | $9,126,684 | 6,565,960 |
| Cerus Corp | +477,858 | +13.76% | $9,402,416 | 3,950,595 |
| Erasca Inc | +67,429 | +5.34% | $19,504,470 | 1,330,455 |
| Compugen LTD | +402,528 | +12.64% | $8,536,548 | 3,586,785 |
| Savara Inc | +163,374 | +12.05% | $7,837,178 | 1,518,833 |
| Solid Biosciences Inc | +91,887 | +13.75% | $5,497,237 | 760,337 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | -966,972 | -79.63% | $4,651,458 | 247,418 |
| Enliven Therapeutics Inc | -367,930 | -75.18% | $5,567,360 | 121,452 |
| Dianthus Therapeutics Inc | -153,418 | -39.34% | $20,831,045 | 236,582 |
| Praxis Precision Medicines I | -45,926 | -69.92% | $5,752,666 | 19,753 |
| Ascendis Pharma A/s | -54,059 | -26.21% | $34,670,030 | 152,175 |
| Aclaris Therapeutics Inc | -1,707,941 | -87.74% | $1,254,726 | 238,541 |
| Oruka Therapeutics Inc | -104,884 | -29.73% | $20,649,090 | 247,918 |
| Oric Pharmaceuticals Inc | -578,321 | -78.27% | $2,162,635 | 160,552 |
| Urogen Pharma LTD | -153,290 | -11.77% | $46,671,234 | 1,148,689 |
| Zenas Biopharma Inc | -175,732 | -34.47% | $9,009,517 | 334,057 |
| Monte Rosa Therapeutics Inc | -212,112 | -6.38% | $37,135,382 | 3,112,773 |
| Benitec Biopharma Inc | -236,717 | -34.82% | $4,431,090 | 443,109 |
| Disc Medicine Inc | -35,488 | -42.86% | $3,097,044 | 47,312 |
| Definium Therapeutics Inc | -54,054 | -13.51% | $13,166,705 | 345,946 |
| Camp4 Therapeutics Corp | -470,531 | -71.99% | $739,575 | 183,063 |
| Contineum Therapeutics Inc | -137,171 | -46.32% | $2,133,297 | 158,964 |
| Uniqure NV | -48,296 | -46.00% | $1,369,969 | 56,704 |
| Vaxcyte Inc | -19,920 | -13.74% | $7,117,052 | 125,080 |
| Achieve Life Science Inc | -68,228 | -30.03% | $1,285,906 | 158,950 |
| Cellectar Biosciences Inc | -170,610 | -53.03% | $278,057 | 151,118 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Rainier Acquisition Corp. | 13G | 9.67% | 853,875 | Nov 13, 2026 | SEC.gov ↗ |
| IRulya Therapeutics Inc | 13G | 7.9% | 880,255 | Nov 13, 2026 | SEC.gov ↗ |
| Sagimet Biosciences Inc | 13G | 6.1% | 3,745,990 | Nov 13, 2026 | SEC.gov ↗ |
| Tela Bio, Inc. | 13G amendment | 4.8% | 2,137,201 | Aug 14, 2026 | SEC.gov ↗ |
| Kalvista Pharmaceuticals, Inc. | 13G amendment | 0% | 0 | Aug 14, 2026 | SEC.gov ↗ |
| Elutia Inc. | 13G amendment | 4.9% | 2,192,980 | Aug 14, 2026 | SEC.gov ↗ |
| Cellectar Biosciences Inc | 13G | 9.99% | 851,285 | Aug 14, 2026 | SEC.gov ↗ |
| NextCure, INC. | 13G amendment | 4.9% | 176,057 | May 13, 2026 | SEC.gov ↗ |
| Helix Acquisition Corp. III | 13G | 6.8% | 1,208,986 | May 13, 2026 | SEC.gov ↗ |
| Fractyl Health Inc | 13G amendment | 2.3% | 3,606,386 | May 13, 2026 | SEC.gov ↗ |
| Avalo Therapeutics, Inc. | 13G | 2.83% | 524,436 | Feb 10, 2026 | SEC.gov ↗ |
| iBio, Inc. | 13G | 9.99% | 2,181,422 | Nov 14, 2025 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (3)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Venture capital funds filing Form D (1)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Jun 4, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures